Donnerstag, 25. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Study of Palbociclib in MLL-rearranged Acute Leukemias

Rekrutierend

NCT-Nummer:
NCT02310243

Studienbeginn:
Juli 2015

Letztes Update:
16.04.2019

Wirkstoff:
Palbociclib

Indikation (Clinical Trials):
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University of Ulm

Collaborator:
Pfizer, National Center for Tumor Diseases, Heidelberg,

Studienlocations
(3 von 24)

Darmkrebszentrum Universitätsklinikum Düsseldorf
Moorenstraße 5
40225 Düsseldorf
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Thomas Schroeder, MD
E-Mail: thomas.schroeder@med.uni-duesseldorf.de» Ansprechpartner anzeigen
Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH
45239 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Mohammed Wattad, MD
E-Mail: m.wattad@kliniken-essen-sued.de» Ansprechpartner anzeigen
Leberkrebszentrum Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Michael Heuser, MD
E-Mail: heuser.michael@mh-hannover.de» Ansprechpartner anzeigen
Städtisches Klinikum Karlsruhe gGmbH
76133 Karlsruhe
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Mark Ringhoffer, MD
E-Mail: mark.ringhoffer@klinikum-karlsruhe.com» Ansprechpartner anzeigen
Hautkrebszentrum Kiel am Universitätsklinikum Schleswig-Holstein Campus Kiel
UKSH, Campus Kiel, Rosalind-Franklin-Straße 7
24105 Kiel
(Schleswig-Holstein)
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Heinz-August Horst, MD
E-Mail: h.horst@med2.uni-kiel.de» Ansprechpartner anzeigen
Universitätsmedizin der Johannes Gutenberg-Universität
55131 Mainz
(Rheinland-Pfalz)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Thomas Kindler, MD
E-Mail: thomas.kindler@unimedizin-mainz.de» Ansprechpartner anzeigen
University Hospital of Ulm
89081 Ulm
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Peter Paschka, MD
Phone: 0049-731-500
Phone (ext.): 45521
E-Mail: peter.paschka@uniklinik-ulm.de» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label

- Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and glioblastoma, this regimen will be chosen for the first dose to be evaluated in the phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib for the phase IIa is defined.

- Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest. Based on the optimal two-stage design of Simon, 21 patients are treated in the first stage. If results are positive, 29 additional patients will be recruited into the second stage of the study. An efficacy of the investigational therapy will be rejected in the first stage of 21 treated patients if two or less patients achieve complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during this first stage, the trial is intended to be continued in the second stage with a total sample size of 50 patients.

Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient out): July 2018 The treatment duration of an individual patient is estimated to be 2-6 months, but may be unlimited in patients with sustained response ("case-by-case decision").

Observation time per patient after entry into the study (incl. treatment) is at least 12 months.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according to the 2008 WHO Classification

- Patients with MLL-rearranged leukemia who are refractory to standard induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

- Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

- Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for intensive first-line therapy

- Genetic/histologic/immunohistologic assessment in one of the central laboratories

- Age ≥ 18 years, no upper age limit

- WHO performance status of ≤ 2

- No prior chemotherapy two weeks before study entry except hydroxyurea to control hyperleukocytosis

- Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).

- Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for three months after the last dose of therapy.

- Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.

- Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for three months after therapy is stopped, even if they have undergone successful vasectomy.

- Signed written informed consent

Exclusion Criteria:

- Prior treatment with palbociclib

- Performance status > 2 according to WHO criteria

- Organ insufficiency: creatinine > 1.5 x upper normal serum level; bilirubin, AST, or AP > 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder

- Uncontrolled infection

- Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.

- Severe neurologic or psychiatric disorder interfering with ability of giving informed consent

- Known or suspected active alcohol or drug abuse

- Known positivity for HIV, active HAV, HBV, or HCV infection

- Bleeding disorder unrelated to leukemia

- Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is allowed)

- QTc > 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes

- Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)

- No consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation

- No consent for biobanking

Studien-Rationale

Primary outcome:

1. Number of Participants with Adverse Events (Time Frame - 12 months):
Safety assessments

2. Maximum tolerated dose of palbociclib (Time Frame - 12 months)

3. overall response rate (Time Frame - 12 months)

Secondary outcome:

1. Relapse-free survival (Time Frame - three years)

2. Overall survival (Time Frame - three years)

3. Evaluation of target (CDK6) inhibition by palbociclib (Time Frame - three years)

4. Assessment of Quality of life (Time Frame - 6 months)

Geprüfte Regime

  • Palbociclib (PD-0332991-00):
    oral, once daily (125mg, 100mg or 75mg) for 21 days

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Study of Palbociclib in MLL-rearranged Acute Leukemias"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.